EpiBiologics: Valuation, Funding & Investors
EpiBiologics is a biotech company developing tissue-selective extracellular protein degradation therapeutics using a proprietary modular bispecific antibody platform (EpiTAC). The company focuses on targeted degradation of disease-driving membrane and soluble proteins to create novel therapies in oncology and immunology.
Leadership & Board
- Current Number of Employees
- 50
- Current LinkedIn Followers
- 5,547
Latest Estimated Valuation
- Total Amount Raised
- $107M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $107M
- Latest Funding Round
- Series B
Company Momentum Positive
EpiBiologics LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
EpiBiologics had 50 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
EpiBiologics had 5,547 followers as of October 26, 2026. The number of followers increased by 18 (0.33%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 08, 2026 | Series B | $107.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Samsara BioCapital | Series B |
| GV | Series B |
| Novartis Venture Fund | Series B |
| Digitalis Ventures | Series B |
| Avego Bioscience Capital | Series B |
| Polaris Partners | Series B |
| Vivo Capital | Series B |
| Mission BioCapital | Series B |
Similar Companies
A snapshot of private companies similar to EpiBiologics, helping you discover and navigate related company profiles.
Related News and Analysis
